Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2012

01.07.2012 | Urologic Oncology

Adjuvant Surgery in Testicular Cancer Patients Undergoing Postchemotherapy Retroperitoneal Lymph Node Dissection

verfasst von: Hooman Djaladat, MD, Craig Nichols, MD, Siamak Daneshmand, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the clinicopathologic characteristics of patients undergoing adjuvant surgery during postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).

Methods

From 2004 to 2010, 85 testicular cancer patients underwent PC-RPLND by a single surgeon (S.D.). A bilateral template approach was utilized with nerve-sparing technique whenever feasible. The clinicopathologic and outcome of patients who underwent removal of any organ or structure during PC-RPLND were reviewed.

Results

Of 85 patients undergoing PC-RPLND, 28 (33%) required adjuvant procedures. Thirteen (15%) required vascular procedures including cavotomy/caval resection in 6, aortic resection in 8, common iliac vessels resection in 4, and renal vessels resection/reimplant in 2. Twelve patients (14%) required adjuvant nephrectomy (ten of 12 left-sided). There was one ureteral resection with appendiceal substitution, one partial duodenectomy, two cholecystectomy, two thoracotomies, four liver resection/biopsy, and one neck dissection. There were eight early complications (28%), including vocal cord paralysis, brachial plexus injury, lower extremities compartment syndrome, thigh numbness, upper gastrointestinal bleeding, retroperitoneal hematoma, and alcohol withdrawal. No perioperative death was reported. Retroperitoneal pathology revealed mature teratoma in 11 patients (39%), fibrosis in 8 (28%), and viable germ cell tumor (GCT) in 9 (32%). A total of 75, 82, and 66% of patients with fibrosis, teratoma, and viable GCT, respectively, had no evidence of recurrence at a mean follow-up of 18 months.

Conclusions

Many patients undergoing PC-RPLND require adjuvant surgery, including vascular procedures and nephrectomy. The excellent outcomes associated with low operative morbidity and mortality validates such aggressive surgical approaches performed by experienced surgeons.
Literatur
1.
Zurück zum Zitat Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol. 2006;176:1996–9.PubMedCrossRef Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol. 2006;176:1996–9.PubMedCrossRef
2.
Zurück zum Zitat Kollmannsberger C, Daneshmand S, Hansen E, et al. Testis cancer. In: Hong WK, Bast RC, Hait WN, et al., editors. Cancer medicine. 8th ed. Shelton: PMPH-USA; 2010. p. 1263–1288. Kollmannsberger C, Daneshmand S, Hansen E, et al. Testis cancer. In: Hong WK, Bast RC, Hait WN, et al., editors. Cancer medicine. 8th ed. Shelton: PMPH-USA; 2010. p. 1263–1288.
3.
Zurück zum Zitat Carver BS, Motzer RJ, Bajorin D, Stasi J, Bosl GJ, Sheinfeld J. Post-chemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumors: the impact of time. J Clin Oncol. 2005;23(16 Suppl., Pt. 1 of 2):4581.CrossRef Carver BS, Motzer RJ, Bajorin D, Stasi J, Bosl GJ, Sheinfeld J. Post-chemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumors: the impact of time. J Clin Oncol. 2005;23(16 Suppl., Pt. 1 of 2):4581.CrossRef
4.
Zurück zum Zitat Donohue JP, Leviovitch I, Foster RS, et al. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998;16:65–71.PubMed Donohue JP, Leviovitch I, Foster RS, et al. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998;16:65–71.PubMed
5.
Zurück zum Zitat Nash PA, Leibovitch I, Foster RS, et al. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J Urol. 1998;159:707–10.PubMedCrossRef Nash PA, Leibovitch I, Foster RS, et al. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J Urol. 1998;159:707–10.PubMedCrossRef
6.
Zurück zum Zitat Heidenreich A, Ohlmann C, Hegele A, et al. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol. 2005;47:64–71.PubMedCrossRef Heidenreich A, Ohlmann C, Hegele A, et al. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol. 2005;47:64–71.PubMedCrossRef
7.
Zurück zum Zitat Donohue JP, Foster RS. Management of retroperitoneal recurrences. Seminoma and nonseminoma. Urol Clin North Am. 1994;21:761–72.PubMed Donohue JP, Foster RS. Management of retroperitoneal recurrences. Seminoma and nonseminoma. Urol Clin North Am. 1994;21:761–72.PubMed
8.
Zurück zum Zitat Christmas TJ, Smith GL, Kooner R. Vascular interventions during post-chemotherapy retroperitoneal lymph-node dissection for metastatic testis cancer. Eur J Surg Oncol. 1998;24:292–7.PubMedCrossRef Christmas TJ, Smith GL, Kooner R. Vascular interventions during post-chemotherapy retroperitoneal lymph-node dissection for metastatic testis cancer. Eur J Surg Oncol. 1998;24:292–7.PubMedCrossRef
9.
Zurück zum Zitat Duty B, Daneshmand S. Resection of the inferior vena cava without reconstruction for urologic malignancies. Urology. 2009;74:1257–62.PubMedCrossRef Duty B, Daneshmand S. Resection of the inferior vena cava without reconstruction for urologic malignancies. Urology. 2009;74:1257–62.PubMedCrossRef
10.
11.
Zurück zum Zitat Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg. 1998;28:808–14.PubMedCrossRef Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg. 1998;28:808–14.PubMedCrossRef
12.
Zurück zum Zitat Mosharafa AA, Foster RS, Koch MO, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol. 2004;171:1839–41.PubMedCrossRef Mosharafa AA, Foster RS, Koch MO, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol. 2004;171:1839–41.PubMedCrossRef
13.
Zurück zum Zitat Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993;11:1294–9.PubMed Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993;11:1294–9.PubMed
14.
15.
Zurück zum Zitat Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 1995;153:976–80.PubMedCrossRef Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 1995;153:976–80.PubMedCrossRef
16.
Zurück zum Zitat Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol. 1999;17:263–7.PubMedCrossRef Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol. 1999;17:263–7.PubMedCrossRef
17.
Zurück zum Zitat McKiernan JM, Motzer RJ, Bajorin DF, et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 2003;62:732–6.PubMedCrossRef McKiernan JM, Motzer RJ, Bajorin DF, et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 2003;62:732–6.PubMedCrossRef
Metadaten
Titel
Adjuvant Surgery in Testicular Cancer Patients Undergoing Postchemotherapy Retroperitoneal Lymph Node Dissection
verfasst von
Hooman Djaladat, MD
Craig Nichols, MD
Siamak Daneshmand, MD
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2012
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2284-8

Weitere Artikel der Ausgabe 7/2012

Annals of Surgical Oncology 7/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.